- A Phase 3 clinical trial, IMpower131, assessing Roche (OTCQX:RHHBY) unit Genentech's TECENTRIQ (atezolizumab) plus chemo for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) met one co-primary endpoint.
- The study demonstrated that TECENTRIQ plus carboplatin and Celgene (NASDAQ:CELG)'s ABRAXANE (albumin-bound paclitaxel; nab-paclitaxel) extended progression-free survival (PFS) compared to chemo alone.
- On a preliminary basis, TECENTRIQ's effect on overall survival (OS), the other co-primary endpoint, was not statistically significant.
- Per the statistical analysis plan, Arm B (TECENTRIQ + carboplatin + nab-paclitaxel) must show a statistically significant effect on OS versus Arm C (carboplatin + nab-paclitaxel) before an analysis comparing OS and PFS between Arm A (TECENTRIQ + carboplatin + paclitaxel) and Arm C can be made.
- The study will continue as planned. The data will be submitted for presentation at a future oncology conference (ASCO).
- Now read: Roche To Acquire Flatiron Health For .9 Billion
Original article